Micro RNA Genetic Signature in NSCLC Egyptian Patients

October 21, 2016 updated by: Adel Salah Bediwy

Micro RNA Genetic Signature in Non-small Cell Lung Cancer Egyptian Patients

This study will be carried out on 40 subjects at Chest department Tanta university hospital

The subjects will be classified into three groups:

  • Group I: will include ten non smoker volunteers (control group I).
  • GroupII: will include ten smoker volunteers (control groupII).
  • Group III: will include twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy.

Study Overview

Status

Completed

Conditions

Detailed Description

The patients and control groups will be subjected to the following:

  • Complete history taking and complete general examination.
  • Complete chest examination.
  • Radiological assessment including chest x ray (posteroanterior and lateral view).
  • Computed tomography (CT) chest for all patients in group III and when needed in group I and II.

  • Laboratory investigations:

    • Complete blood picture
    • Fasting and post parandial blood sugar level
    • liver function tests
    • kidney function tests (urea and creatinine).
    • Prothrombine time and activity.
    • Zeil-Neelsen staining of sputum.
    • Tumour markers including α Fetoprotein, Carcino Embryonic antigen (CEA), CA19-9, CA 125, CA15-3 and others.
  • Venous blood samples will be collected from peripheral blood (5 ml) under complete aseptic technique. Serum samples will be obtained by centrifugation. Isolation of total RNA from serum pools will be performed. RNA profiles and quantification will be assessed using Microarray.
  • Lung biopsy either transbronchial via bronchoscopy or peripherally via ultrasound , CT guided, thoracoscopy or open lung biopsy will be performed with isolation of total RNA from lung tissue biopsy. RNA profiles and quantification will be assessed using Microarray.
  • Bronchoalveolar lavage will be performed with isolation of total RNA from it. RNA profiles will be assessed using Microarray.

Ethical considerations:

  1. Informed consent will be taken from all subject's and include:

    A. The aim of research. B. All data are confidential. C. All data will be used in research only.

  2. For patient's privacy:

    A. There will be a code number for each patient in special folder. B. The results of research will be used in scientific publishing only.

  3. Unexpected risks that appear during the courses of research will be cleared to the participants and the ethical committee on time.

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Gharbia
      • Tanta, Gharbia, Egypt, 31111
        • Chest Department, Faculty of Medicine, Tanta University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

This study will be carried out on 40 subjects at Chest department Tanta university hospital.

The subjects will be classified into three groups:

  • Group I: will include ten non smoker volunteers (control group I).
  • GroupII: will include ten smoker volunteers (control groupII).
  • Group III: will include twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy.

Description

Inclusion Criteria:

  • Inclusion criteria for patients:

Non small cell lung cancer patients recently diagnosed who did not receive chemotherapy, surgery or radiation therapy.

-

Exclusion Criteria:

  • Exclusion criteria for patients:
  • Diagnosis of asthma or COPD.
  • Broncheiactasis.
  • upper/lower respiratory tract infection in the preceding 4 weeks.
  • Active pulmonary tuberculosis.
  • Associated cancer beside lung cancer.
  • Patients who received chemotherapy, surgery or radiation therapy previous to the sample collection.

Exclusion criteria for control subjects:

  • Diagnosis of asthma or COPD.
  • Broncheiactasis.
  • Upper/lower respiratory tract infection in the preceding 4 weeks.
  • Active pulmonary tuberculosis
  • Smoking in group I.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Control group 1
ten non smoker volunteers
Control group 2
ten smoker volunteers
NSCLC patients
twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Detect micro RNA genetic signature pattern in non-small cell lung cancer Egyptian patients assessed using Microarray
Time Frame: one year
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Adel Salah Bediwy

Investigators

  • Principal Investigator: Abdel-Aziz A Zidan, PHD, Director of Genomics and Proteomics Unit, Center of Excellence in Cancer Research, Tanta University
  • Study Chair: Amgad A Farahat, MD, Chest Department, Faculty of Medicine, Tanta University
  • Principal Investigator: Ayman H Abd El-Zaher, MD, Chest Department, Faculty of Medicine, Tanta University
  • Principal Investigator: Said M Hammad, MD, Clinical Pathology Department, Faculty of Medicine, Tanta University
  • Principal Investigator: Adel S Bediwy, MD, Chest Department, Faculty of Medicine, Tanta University
  • Principal Investigator: Ayman A Al Saka, MD, Pathology Department, Faculty of Medicine, Tanta University
  • Principal Investigator: Samar A Mansour, Master, Chest Department, Faculty of Medicine, Tanta University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2015

Primary Completion (Actual)

January 1, 2016

Study Completion (Actual)

August 1, 2016

Study Registration Dates

First Submitted

May 13, 2015

First Submitted That Met QC Criteria

May 14, 2015

First Posted (Estimate)

May 15, 2015

Study Record Updates

Last Update Posted (Estimate)

October 24, 2016

Last Update Submitted That Met QC Criteria

October 21, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2858/11/14

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe